Common chemicals acting together may be carcinogenic to humans
the ONA take:
Common chemicals not considered to be carcinogenic to humans at low doses may act together to increase cancer risk, according a 3-year investigation conducted by a task force comprised of nearly 200 researchers from 28 countries.
Of the 85 chemicals studied, 50 were found to disrupt normal cell function in ways that are known to be associated with early signs of cancer.
Chemicals studied included bisphenol A (BPA), a chemical used in plastics, rotenone, an insecticide, paraquat, a herbicide, triclosan, an antibacterial agent, and EDTA, a metal-ion-binding compound used in manufacturing and medicine.
"Our findings also suggest these molecules may be acting in synergy to increase cancer activity," said William Bisson, an assistant professor and cancer researcher at OSU and a team leader on the study.
EDTA alone does not cause gene mutations, but when exposed to that and something else that is mutagenic, the effect of DNA repair disruption is enhanced.
The findings suggest that more research is warranted to evaluate early exposure to these common chemicals and how those chemicals affect the early stages of cancer development.
Common chemicals not considered to be carcinogenic to humans at low doses may act together to increase cancer risk.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|